Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P42704

UPID:
LPPRC_HUMAN

ALTERNATIVE NAMES:
130 kDa leucine-rich protein; GP130

ALTERNATIVE UPACC:
P42704; A0PJE3; A8K1V1; Q53PC0; Q53QN7; Q6ZUD8; Q7Z7A6; Q96D84

BACKGROUND:
Leucine-rich PPR motif-containing protein, mitochondrial, known alternatively as GP130, is integral to RNA metabolism across nuclear and mitochondrial environments. It binds to HNRPA1-associated poly(A) mRNAs, playing a role in mRNA maturation and export. Its functions extend to the regulation of mitochondrially encoded genes and gluconeogenic genes, in cooperation with PPARGC1A, and it is implicated in the transcription regulation of genes MDR1 and MVP.

THERAPEUTIC SIGNIFICANCE:
The protein's association with Mitochondrial complex IV deficiency, nuclear type 5, underscores its potential as a target for therapeutic intervention. Understanding the role of GP130 could pave the way for novel treatments for this and related mitochondrial disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.